BR0014428A - Composto, pró medicamento de um composto, composição farmacêutica, uso de um composto, e, métodos para antagonizar ccr5, e, para produzir um composto - Google Patents

Composto, pró medicamento de um composto, composição farmacêutica, uso de um composto, e, métodos para antagonizar ccr5, e, para produzir um composto

Info

Publication number
BR0014428A
BR0014428A BR0014428-2A BR0014428A BR0014428A BR 0014428 A BR0014428 A BR 0014428A BR 0014428 A BR0014428 A BR 0014428A BR 0014428 A BR0014428 A BR 0014428A
Authority
BR
Brazil
Prior art keywords
compound
substituted
group
bond
hydrocarbon group
Prior art date
Application number
BR0014428-2A
Other languages
English (en)
Other versions
BRPI0014428B1 (pt
BRPI0014428B8 (pt
Inventor
Shinichi Imamura
Shohei Hashiguchi
Taeko Hattori
Osamu Nishimura
Naoyuki Kanzaki
Masanori Baba
Yoshihiro Sugihara
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26554466&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0014428(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of BR0014428A publication Critical patent/BR0014428A/pt
Publication of BRPI0014428B1 publication Critical patent/BRPI0014428B1/pt
Publication of BRPI0014428B8 publication Critical patent/BRPI0014428B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMPOSTO, PRó MEDICAMENTO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODOS PARA ANTAGONIZAR CCR5, E, PARA PRODUZIR UM COMPOSTO". Um composto da fórmula (I) (em que R^ 1^ é um átomo de hidrogênio, um grupo hidrocarboneto que pode ser substituído, um grupo heterocíclico não aromático que pode ser substituído, R^ 2^ é um grupo hidrocarboneto que pode ser substituído, um grupo heterocíclico não aromático que pode ser substituído ou R^ 1^ e R^ 2^ podem combinar um com o outro juntos com A para formar um grupo heterocíclico que pode ser substituído; A é N ou N^ +^-R^ 5^<sym>-Y^ -^(R^ 5^ é um grupo hidrocarboneto; Y^ -^ é um contra ânion); R^ 3^ é um grupo hidrocarboneto cíclico que pode ser substituído ou um grupo heterocíclico que pode ser substituído; n é 0 ou 1; R^ 4^ é um átomo de hidrogênio, um grupo hidrocarboneto que pode ser substituído, um grupo heterocíclico que pode ser substituído, um grupo alcóxi que pode ser substituído, um grupo arilóxi que pode ser substituído ou um grupo amino que pode ser substituído, E é um grupo hidrocarboneto alifático bivalente que pode ser substituído por grupo(s) outros que não oxo; G^ 1^ é uma ligação, CO ou SO~ 2~; G^ 2^ é CO, SO~ 2~, NHCO, CONH ou OCO; J é metina ou um átomo de nitrogênio; e cada um de Q e R é uma ligação ou um hidrocarboneto alifático bivalente C~ 1-3~ que pode ser substituído; contanto que J seja metina quando G^ 2^ é OCO, que um de Q e R não seja uma ligação quando o outro é uma ligação e que cada um de Q e R não seja substituído por grupo(s) oxo quando G^ 1^ é uma ligação) ou um sal deste têm uma atividade antagonística ao CCR5 potente e podem ser vantajosamente usados para o tratamento ou a prevenção de doença infecciosa de vários HIV em seres humanos (por exemplo, a AIDS).
BRPI0014428A 1999-10-01 2000-09-29 composto, composição farmacêutica, e, uso de um composto para o tratamento ou prevenção da doença infecciosa do hiv BRPI0014428B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP28208899 1999-10-01
JP2000046749 2000-02-18
PCT/JP2000/006755 WO2001025200A1 (en) 1999-10-01 2000-09-29 Cyclic amine compounds as ccr5 antagonists

Publications (3)

Publication Number Publication Date
BR0014428A true BR0014428A (pt) 2002-06-11
BRPI0014428B1 BRPI0014428B1 (pt) 2016-08-02
BRPI0014428B8 BRPI0014428B8 (pt) 2021-05-25

Family

ID=26554466

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0014428A BRPI0014428B8 (pt) 1999-10-01 2000-09-29 composto, composição farmacêutica, e, uso de um composto para o tratamento ou prevenção da doença infecciosa do hiv

Country Status (23)

Country Link
US (2) US6562978B1 (pt)
EP (2) EP1886994A1 (pt)
JP (2) JP3814136B2 (pt)
KR (1) KR20020060190A (pt)
CN (1) CN1390201A (pt)
AR (1) AR025884A1 (pt)
AT (1) ATE400555T1 (pt)
AU (1) AU7448700A (pt)
BR (1) BRPI0014428B8 (pt)
CA (2) CA2385938C (pt)
CO (1) CO5380013A1 (pt)
CY (1) CY1108403T1 (pt)
DE (1) DE60039446D1 (pt)
DK (1) DK1220842T3 (pt)
ES (1) ES2310173T3 (pt)
HK (1) HK1046905A1 (pt)
HU (1) HUP0300138A3 (pt)
NO (1) NO20021450L (pt)
PE (1) PE20010628A1 (pt)
PL (1) PL203984B1 (pt)
PT (1) PT1220842E (pt)
WO (1) WO2001025200A1 (pt)
ZA (1) ZA200202593B (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
AU2001288110A1 (en) * 2000-09-27 2002-04-08 Takeda Chemical Industries Ltd. Spiro compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
EP1354587A1 (en) * 2000-12-22 2003-10-22 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
CN1494529A (zh) * 2001-01-18 2004-05-05 武田药品工业株式会社 苄基哌啶化合物的制备方法
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
WO2002088089A1 (fr) * 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
CA2484384A1 (en) * 2002-04-19 2003-10-30 Takeda Pharmaceutical Company Limited Preventives for hiv infection
WO2003090748A1 (fr) * 2002-04-24 2003-11-06 Takeda Pharmaceutical Compay Limited. Utilisation de composes a antagonisme anti-ccr
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
AU2003266528A1 (en) * 2002-09-20 2004-04-08 Takeda Pharmaceutical Company Limited Cyclic amine compound, process for producing the same, and use
EP1553098A1 (en) * 2002-10-18 2005-07-13 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
AU2003290323A1 (en) * 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
CA2548393A1 (en) 2003-12-11 2005-06-30 Anormed Inc. Chemokine receptor binding compounds
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
SE0403084D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Chemical process
BRPI0516407A (pt) * 2004-12-24 2008-09-02 Prosidion Ltd agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes
EP1831164A1 (en) 2004-12-24 2007-09-12 AstraZeneca AB Heterocyclic compounds as ccr2b antagonists
WO2006130426A2 (en) * 2005-05-27 2006-12-07 Kemia, Inc. Modulators of ccr-5 activity
AU2013200480B2 (en) * 2006-02-28 2016-06-09 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
NZ595571A (en) 2006-02-28 2013-04-26 Helicon Therapeutics Inc Pyrazole compounds and uses thereof
JP2009528363A (ja) 2006-02-28 2009-08-06 ヘリコン セラピューティクス，インコーポレイテッド Ｐｄｅ４インヒビターとしての治療用ピペラジン
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2008073450A2 (en) * 2006-12-12 2008-06-19 Georgetown University Benzamide compounds
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8222243B2 (en) 2007-08-27 2012-07-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
JP2010540629A (ja) 2007-10-04 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション カルシウムチャネル遮断薬としての置換アリールスルホン誘導体
WO2011102436A1 (ja) * 2010-02-17 2011-08-25 国立大学法人京都大学 ＴＧＦ－βシグナル伝達阻害剤
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
CN101921224B (zh) * 2010-05-21 2012-01-18 中国人民解放军军事医学科学院生物工程研究所 1-（3-氨基丙基）哌嗪-4-氨基酰胺类化合物及其制备方法与应用
KR200453948Y1 (ko) * 2011-02-28 2011-06-09 최문희 파마로드
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN103130709B (zh) * 2011-11-22 2017-04-12 常州亚邦制药有限公司 具有抗hiv活性的3‑氨基丙酸哌啶酰胺类化合物，合成方法及用途
KR20190007106A (ko) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
NZ743463A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
DK2961732T3 (en) 2013-02-28 2017-07-10 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
WO2014161888A1 (en) 2013-04-03 2014-10-09 Janssen R&D Ireland N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
LT2997019T (lt) 2013-05-17 2018-11-26 Janssen Sciences Ireland Uc Sulfamoiltiofenamido dariniai ir jų panaudojimas kaip vaistų hepatito b gydymui
LT3024819T (lt) 2013-07-25 2018-06-11 Janssen Sciences Ireland Uc Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui
JP6452119B2 (ja) * 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP3102225B1 (en) 2014-02-05 2020-03-25 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
CN111867582A (zh) 2018-03-14 2020-10-30 爱尔兰詹森科学公司 衣壳组装调节剂给药方案
US20220363639A1 (en) * 2018-07-31 2022-11-17 The Trustees Of The University Of Pennsylvania Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
JP2022532526A (ja) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染又はｈｂｖ誘導性疾患の処置において有用なアミド誘導体
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
CN117098560A (zh) * 2021-04-23 2023-11-21 中国人民解放军军事科学院军事医学研究院 抗病毒多肽化合物
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
WO2023107547A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Azetidine and spiroazetidine compounds and uses thereof
WO2023243601A1 (ja) * 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203988A (en) * 1975-11-12 1980-05-20 Merck & Co., Inc. Pyridinyl ureas and pharmaceutical use
JPH0680054B2 (ja) * 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
EP1120416A1 (en) * 1993-04-05 2001-08-01 Pharmaceutical Discovery Corporation Pyrido[2.3-b][1,4]benzodiazepinones as M2 receptor ligand for the treatment of neurological disorders
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
AU2654399A (en) 1998-02-02 1999-08-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
CN1494529A (zh) * 2001-01-18 2004-05-05 武田药品工业株式会社 苄基哌啶化合物的制备方法

Also Published As

Publication number Publication date
CA2385938A1 (en) 2001-04-12
EP1886994A1 (en) 2008-02-13
ZA200202593B (en) 2003-04-03
DE60039446D1 (de) 2008-08-21
CN1390201A (zh) 2003-01-08
HK1046905A1 (en) 2003-01-30
HUP0300138A2 (en) 2003-05-28
CA2608807A1 (en) 2001-04-12
PL203984B1 (pl) 2009-11-30
AR025884A1 (es) 2002-12-18
US6562978B1 (en) 2003-05-13
ES2310173T3 (es) 2009-01-01
BRPI0014428B1 (pt) 2016-08-02
PE20010628A1 (es) 2001-06-18
ATE400555T1 (de) 2008-07-15
CY1108403T1 (el) 2014-02-12
CO5380013A1 (es) 2004-03-31
WO2001025200A1 (en) 2001-04-12
DK1220842T3 (da) 2008-11-10
EP1220842A1 (en) 2002-07-10
JP3814136B2 (ja) 2006-08-23
EP1220842B1 (en) 2008-07-09
US7348324B2 (en) 2008-03-25
HUP0300138A3 (en) 2003-06-30
CA2385938C (en) 2010-02-16
AU7448700A (en) 2001-05-10
NO20021450L (no) 2002-06-03
US20030114443A1 (en) 2003-06-19
NO20021450D0 (no) 2002-03-22
BRPI0014428B8 (pt) 2021-05-25
KR20020060190A (ko) 2002-07-16
JP2001302633A (ja) 2001-10-31
PL356034A1 (en) 2004-06-14
PT1220842E (pt) 2008-10-17
JP2003048880A (ja) 2003-02-21

Similar Documents

Publication Publication Date Title
BR0014428A (pt) Composto, pró medicamento de um composto, composição farmacêutica, uso de um composto, e, métodos para antagonizar ccr5, e, para produzir um composto
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
PL396946A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
HUP0202867A2 (hu) CCR5 antagonistákként alkalmazható piperazinszármazékok és ezeket tartalmazó gyógyszerkészítmények
ATE355064T1 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
HUP0300721A2 (hu) Antibakteriális hatású (amino-piperidino)-kinolinok és aza-izoszter analógjaik, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
BG104849A (en) Indolyl-3-glyoxylic acid derivatives with antitumoral activity
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
HUP0402458A2 (hu) Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek
MXPA03008528A (es) Medicamentos que contienen derivados de triazaspiro [5.5] undecano como el ingrediente activo.
AR015312A1 (es) Compuestos inhibidores no peptidilicos de la union a las celulas dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunesy respiratorias, composicion farmaceutica y uso de los compuestos en la preparacion de medicamentos
BR0012697A (pt) Inibidores da diferenciação de th2
EP1201239A4 (en) CYCLIC AMINES AS CCR3 ANTAGONISTS
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
ES2061848T3 (es) Compuestos triciclos, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
BR0100155A (pt) Azabenzimidazóis aril substituìdos e sua utilização no tratamento de hiv e doenças relacionadas com aids
HUP0401018A2 (hu) 2H-1-benzopirán-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények
DE60318874D1 (en) Pyrazolderivate
TR200002831A2 (tr) Kinolin-4-İl türevleri I
AR029900A1 (es) Compuestos derivados de n-(heterociclil)benceno- o piridinsulfonamida, procedimiento para su preparacion y medicamento y composicion farmaceutica que los contienen
HUP0004701A2 (hu) Új dezloratadin sók, az ezeket tartalmazó gyógyászati készítmények és eljárás azok előállítására
HUP0104533A2 (hu) Új pirimidinszármazékok és eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
DE60319254D1 (de) Pyrazolamide zur behandlung von hiv-infektionen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, E 7A ANUIDADES.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B25A Requested transfer of rights approved

Owner name: TOBIRA THERAPEUTICS, INC. (US)

Free format text: TRANSFERIDO DE: TAKEDA CHEMICAL INDUSTRIES, LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/09/2020

B15V Prolongation of time limit allowed